Invenomic is a Delaware limited partnership founded in December 2015. Ali Motamed (“Mr.
Motamed”) is the founder and principal owner of Invenomic. Mr. Motamed is responsible for the
management of the investment strategies employed by Invenomic. Invenomic GP LLC, a Delaware
limited liability company, serves as the general partner of Invenomic. Mr. Motamed is the owner
and the managing member of Invenomic GP LLC.
Invenomic serves as the investment manager and provide discretionary advisory services to certain
private funds, a registered investment company, and a UCITS fund (each a “Fund,” collectively,
the “Funds” or the “Clients.”) Invenomic provides investment advice directly to the applicable
Client and not individually to limited partners or shareholders of the Funds (referred to herein as
“Investors”).
Invenomic may, in the future, organize additional investment vehicles or provide investment
advisory services to other accounts that follow an investment strategy similar to or different from
the investment program of the Clients.
Invenomic seeks to provide the Funds with long term capital appreciation. Invenomic seeks to
achieve each Fund’s investment objective by investing primarily in both long and short positions
in equity securities principally traded in United States markets. Invenomic will, from time to time,
also invest a Fund’s assets in high yield debt obligations and related instruments. In providing
services to Clients, among other things, Invenomic: (i) manages the
Clients’ assets in accordance
with the terms of the applicable Client’s confidential offering memorandum, individual limited
partnership agreement, investment advisory agreement, memorandum and articles of association
or shareholder agreement and other governing documents applicable to each Client (collectively
the “Governing Documents”); (ii) formulates investment objectives; (iii) directs and manages the
investment and reinvestment of the Clients’ respective assets; and (iv) provides, or causes to be
provided, periodic reports to Investors and/or Clients, as applicable.
Investors will not generally be permitted to impose restrictions on the types of investments in
which their respective Fund may invest. Investment restrictions for a Client, if any, will generally
be established in the Governing Documents of the applicable Client. The Funds may enter into
side letters and other agreements and arrangements with certain Investors in the Funds, which may
provide terms and conditions that are more advantageous than those set forth in the applicable
Governing Documents. Such terms and conditions may include special rights to make future
investments in the Funds or other investment vehicles managed by Invenomic, different
transparency rights, and/or different fee terms.
Invenomic does not participate in wrap fee programs.
As of December 31, 2023, Invenomic has approximately $3,711,974,955 in regulatory assets under
management, all of which are managed on a discretionary basis.